Compare Gilead Sciences, Inc. (GILD) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Intuit Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Intuit Inc. trades at $280.5 (market cap $76.51B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Intuit Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | INTU | |
|---|---|---|
Market Cap | $163.51B | $76.51B |
Sector | Health | Technology |
52-Week High | $155.80 | $807.39 |
52-Week Low | $108.22 | $255.07 |
Enterprise Value | $178.05B | $74.97B |
Dividend Yield | 2.49% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Intuit (INTU) trades at $282.43, down 2.52% over the past day, amid a wave of securities fraud investigations related to TurboTax pricing disclosures. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Technical indicators are neutral, with RSI at 55.89 and support at $278.
The outlook is mixed: analyst consensus remains bullish with a $422.88 price target and 71% buy ratings, but legal risks and a recent Goldman Sachs downgrade to sell pose near-term headwinds. Long-term growth driven by AI integration in products like Mailchimp offers upside, though investor sentiment is cautious pending legal clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
